Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Ended
Participants planned
40
Countries
1
Sites
1
Depression
Key facts
- Sponsor
- AlzeCure Pharma AB
- Participant type
- Healthy volunteers
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Psychiatry and Psychology [F] - Mental Disorders [F03], Diseases [C] - Nervous System Diseases [C10]
- Trial duration
- 22 Oct 2025 → 9 Apr 2026
- Decision date (initial)
- 2025-09-10
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Depression
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
AlzeCure Pharma AB
- Sponsor organisation
- AlzeCure Pharma AB
- Address
- Halsovagen 7, Flemingsberg Flemingsberg
- City
- Huddinge
- Postcode
- 141 57
- Country
- Sweden
Scientific contact point
- Organisation
- AlzeCure Pharma AB
- Contact name
- Märta Segerdahl
Public contact point
- Organisation
- AlzeCure Pharma AB
- Contact name
- Märta Segerdahl
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Sweden | Ended | 40 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Sweden | 2025-10-22 | 2026-04-09 | 2025-10-22 | 2026-02-23 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-06-30 | Sweden | Acceptable 2025-09-08
|
2025-09-10 |